The clinical efficacy of Adipromin has been demonstrated in three randomized, double-blind, placebo-controlled clinical trials, published in well-respected medical journals.4, 5, 6 To
validate weight management claims, health professionals and regulatory
agencies alike prefer to see at least two clinical trials published in
the peer-reviewed medical literature.

The second, larger study was a randomized controlled
clinical trial of Adipromin in healthy overweight subjects (n = 140).
The 16-week study compared the use of Adipromin in conjunction with an
1800 calorie/day diet and walking plan to a placebo with the same diet
and walking plan.5

At the end of the study, subjects taking Adipromin showed
significant reductions in body weight (-11.82 pounds vs. -1.92 pounds; p
< 0.0001) and BMI (2.05 kg vs. 0.34 kg/m2; p < 0.0001), compared
with placebo.*

Subjects taking Adipromin had significant reductions in waist
circumference (-2.12 inches vs. -0.67 inches; p < 0.0001) and hip
circumference (-1.77 inches vs. -0.47 inches p < 0.0001) compared
with placebo.*

Subjects taking Adipromin had statistically significant improvement
compared to placebo in their blood lipid profiles (p < 0.0001). *

Subjects taking Adipromin had improved serum adiponectin (p =
0.0071) and serum ghrelin (p = 0.0568) compared to those taking
placebo.*

The third clinical trial was a randomized,
double-blind, placebo-controlled clinical trial that assessed the
effects of 7 days of Adipromin supplementation on resting metabolic rate (RMR), heart rate, blood pressure, and indices of mood in healthy overweight men and women.6 Adipromin
produced significant increases in RMR in healthy overweight men and
women relative to those RMR changes measured in a matched placebo group.* The increase in RMR (up to 15.2% after one week) occurred without concomitant alterations in heart rate or blood pressure and was accompanied by an improved measure of mood.*